The University of North Carolina at Chapel Hill (UNC-CH) has enrolled approximately 65 treatment cases (including 10-15 minority accruals/year) plus 50-120 companion studies annually for the past four years. Our affiliate network is responsible for another 78-99 treatment accruals/year while maintaining excellent data quality control. UNC has broad leadership participation in the Group in Breast, Cancer Prevention and Control, GI, Lymphoma, Molecular Pathology, Pharmaceutics and Experimental Therapeutics, Radiation Oncology and Transplant, and is the research base for a UNC based Minority Initiative Program and a VCU based Minority CCOP. During the past five years, UNC has had four committee chairs, eight committee vice-chairs, seven administrative committee members, 14 modality committee members or modality committee liaisons, 14 scientific committee members or scientific committee liaisons, two Executive Committee members, two members of the Board of Directors, and seven protocol principal investigators. Members from UNC and its affiliates have chaired more than 35 studies and contributed to over 130 manuscripts and abstracts. Faculty at UNC-CH have expanded our commitment and Group leadership in the Breast, Surgery, GU, GI, Lymphoma, Solid Tumor Correlative Sciences, Thoracic, and PET committees (L. Carey, C. Dees, L. Dressler, R. Goldberg, H McLeod, B. O'Neil, R. Pruthi, C. Sartor, T. Shea, and M. Socinski). The addition of Drs. Goldberg (Chair, GI Committee), Howard McLeod (Vice Chair, PET Committee), and Charles Perou (Vice Chair, Breast Committee), have significantly enhanced our role in the Group. We therefore believe that this renewal application reflects the growing and crucial contribution that UNC-CH investigators provide to the Group in leadership, science, and service as well as our continued efforts to increase accrual both at UNC-CH and through affiliate members while maintaining rigorous control of quality data submission.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Internal Medicine/Medicine
Schools of Medicine
Chapel Hill
United States
Zip Code
Martin, Linda W; D'Cunha, Jonathan; Wang, Xiaofei et al. (2016) Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). J Clin Oncol 34:1484-91
Freedman, Rachel A; Seisler, D K; Foster, J C et al. (2016) Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat :
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Dressler, Lynn G; Deal, Allison M; Owzar, Kouros et al. (2015) Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). J Natl Cancer Inst 107:
Wang, Xiaofei; Gu, Lin; Zhang, Ying et al. (2015) Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Lung Cancer 90:281-7
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38

Showing the most recent 10 out of 134 publications